Trial Profile
Phase 1 study to determine the maximum tolerated dose and to assess the safety, pharmacokinetics, and efficacy of AVI-3207 Inj. in patients with neovascular age-related macular degeneration
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 31 Jul 2020
Price :
$35
*
At a glance
- Drugs Timtraxanib (Primary)
- Indications Wet age-related macular degeneration
- Focus Adverse reactions; Therapeutic Use
- Acronyms AVI-3207Inj-P1AMD
- Sponsors Avixgen
- 21 Apr 2020 Status changed from planning to recruiting.
- 26 Sep 2018 New trial record